sGCα1 mediates the negative inotropic effects of NO in cardiac myocytesindependent of changes in calcium handling

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 301, Issue 1, 2011, Pages

  Cawley, Sharon M ^a   Kolodziej, Starsha ^a   Ichinose, Fumito ^a   Brouckaert, Peter ^b   Buys, Emmanuel S ^a   Bloch, Kenneth D ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

3 adrenergic receptor; Cardiaccontractility; Cyclic 3 , 5 guanosine monophosphate; Nitric oxide; Soluble guanylate cyclase

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; CALCIUM ION; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GUANYLATE CYCLASE; GUANYLATE CYCLASE ALPHA1 SUBUNIT; ISOENZYME; NITRIC OXIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CALCIUM SIGNALING; CELL ISOLATION; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HEART LEFT VENTRICLE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; IMMUNOCYTOCHEMISTRY; INOTROPISM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SARCOMERE LENGTH; WILD TYPE;

ADRENERGIC BETA-3 RECEPTOR AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; CALCIUM; CALCIUM SIGNALING; CYCLIC GMP-DEPENDENT PROTEIN KINASES; ETHANOLAMINES; GUANYLATE CYCLASE; IMMUNOHISTOCHEMISTRY; MICE; MICE, KNOCKOUT; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; RECEPTOR, MUSCARINIC M2; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ADRENERGIC, BETA-2; RECEPTORS, ADRENERGIC, BETA-3; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SARCOMERES; SPERMINE;

EID: 79959877520     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01273.2010     Document Type: Article

References (51)

1. Barouch LA, Harrison RW, Skaf MW, Rosas GO, Cappola TP, Kobeissi ZA, Hobai IA, Lemmon CA, Burnett AL, O'Rourke B, Rodriguez ER, Huang PL, Lima JA, Berkowitz DE, Hare JM. Nitricoxide regulates the heart by spatial confinement of nitric oxide synthaseisoforms. Nature 416: 337-339, 2002.
2. Boivin B, Lavoie C, Vaniotis G, Baragli A, Villeneuve LR, Ethier N, Trieu P, Allen BG, Hebert TE. Functional beta-adrenergic receptorsignaling on nuclear membranes in adult rat and mouse ventricularcardiomyocytes. Cardiovasc Res 71: 69-78, 2006.
3. Borlaug BA, Melenovsky V, Marhin T, Fitzgerald P, Kass DA. Sildenafilinhibits beta-adrenergic-stimulated cardiac contractility in humans. Circulation 112: 2642-2649, 2005.
4. Budworth J, Meillerais S, Charles I, Powell K. Tissue distribution of thehuman soluble guanylate cyclases. Biochem Biophys Res Commun 263:696-701, 1999.
5. Buys ES, Sips P, Vermeersch P, Raher MJ, Rogge E, Ichinose F, Dewerchin M, Bloch KD, Janssens S, Brouckaert P. Gender-specifichypertension and responsiveness to nitric oxide in sGCalpha1 knockoutmice. Cardiovasc Res 79: 179-186, 2008.
6. Champion HC, Georgakopoulos D, Takimoto E, Isoda T, Wang Y, Kass DA. Modulation of in vivo cardiac function by myocyte-specificnitric oxide synthase-3. Circ Res 94: 657-663, 2004.
7. Dostmann WR, Taylor MS, Nickl CK, Brayden JE, Frank R, Tegge WJ. Highly specific, membrane-permeant peptide blockers of cGMPdependentprotein kinase Ialpha inhibit NO-induced cerebral dilation. Proc Natl Acad Sci USA 97: 14772-14777, 2000.
8. Ebihara Y, Karmazyn M. Inhibition of beta- but not alpha 1-mediatedadrenergic responses in isolated hearts and cardiomyocytes by nitric oxideand 8-bromo cyclic GMP. Cardiovasc Res 32: 622-629, 1996.
9. Feil R, Lohmann SM, de Jonge H, Walter U, Hofmann F. CyclicGMP-dependent protein kinases and the cardiovascular system: insightsfrom genetically modified mice. Circ Res 93: 907-916, 2003.
10. Fischmeister R, Hartzell HC. Mechanism of action of acetylcholine oncalcium current in single cells from frog ventricle. J Physiol 376: 183-202,1986.
11. Gauthier C, Leblais V, Kobzik L, Trochu JN, Khandoudi N, Bril A, Balligand JL, Le Marec H. The negative inotropic effect of beta3-adrenoceptor stimulation is mediated by activation of a nitric oxidesynthase pathway in human ventricle. J Clin Invest 102: 1377-1384, 1998.
12. Gauthier C, Tavernier G, Charpentier F, Langin D, Le Marec H. Functional beta3-adrenoceptor in the human heart. J Clin Invest 98:556-562, 1996.
13. Gonzalez DR, Beigi F, Treuer AV, Hare JM. Deficient ryanodinereceptor S-nitrosylation increases sarcoplasmic reticulum calcium leak andarrhythmogenesis in cardiomyocytes. Proc Natl Acad Sci USA 104:20612-20617, 2007.
14. Guazzi M, Vicenzi M, Arena R, Guazzi MD. PDE5-inhibition withsildenafil improves left ventricular diastolic function, cardiac geometryand clinical status in patients with stable systolic heart failure: results of a1-year prospective, randomized, placebo-controlled study. Circ Heart Fail4: 8-17, 2011.
15. Hescheler J, Kameyama M, Trautwein W. On the mechanism ofmuscarinic inhibition of the cardiac Ca current. Pflügers Arch 407:182-189, 1986.
16. Heusch G, Post H, Michel MC, Kelm M, Schulz R. Endogenous nitricoxide and myocardial adaptation to ischemia. Circ Res 87: 146-152, 2000.
17. Hofmann FBM, Feil R, Kleppisch T. Mouse models of NO/natriureticpeptide/cGMP kinase signaling. Handbook of Experimental Pharmacology, edited by Offermanns S. Amsterdam, The Netherlands: Elsevier, vol.159, 2004, p. 95-130.
18. Janssens S, Pokreisz P, Schoonjans L, Pellens M, Vermeersch P, Tjwa M, Jans P, Scherrer-Crosbie M, Picard MH, Szelid Z, Gillijns H, Vande Werf F, Collen D, Bloch KD. Cardiomyocyte-specific overexpressionof nitric oxide synthase 3 improves left ventricular performance andreduces compensatory hypertrophy after myocardial infarction. Circ Res94: 1256-1262, 2004.
19. Joe EK, Schussheim AE, Longrois D, Maki T, Kelly RA, Smith TW, Balligand JL. Regulation of cardiac myocyte contractile function byinducible nitric oxide synthase (iNOS): mechanisms of contractile depressionby nitric oxide. J Mol Cell Cardiol 30: 303-315, 1998.
20. Kojda G, Kottenberg K, Nix P, Schluter KD, Piper HM, Noack E. Lowincrease in cGMP induced by organic nitrates and nitrovasodilators improvescontractile response of rat ventricular myocytes. Circ Res 78:91-101, 1996.
21. Kojda G, Kottenberg K, Noack E. Inhibition of nitric oxide synthase andsoluble guanylate cyclase induces cardiodepressive effects in normal rathearts. Eur J Pharmacol 334: 181-190, 1997.
22. Layland J, Li JM, Shah AM. Role of cyclic GMP-dependent proteinkinase in the contractile response to exogenous nitric oxide in rat cardiacmyocytes. J Physiol 540: 457-467, 2002.
23. Lee DI, Vahebi S, Tocchetti CG, Barouch LA, Solaro RJ, Takimoto E, Kass DA. PDE5A suppression of acute beta-adrenergic activation requiresmodulation of myocyte beta-3 signaling coupled to PKG-mediated troponinI phosphorylation. Basic Res Cardiol 105: 337-347.
24. Lim CC, Apstein CS, Colucci WS, Liao R. Impaired cell shortening andrelengthening with increased pacing frequency are intrinsic to the senescentmouse cardiomyocyte. J Mol Cell Cardiol 32: 2075-2082, 2000.
25. Lincoln TM, Dey N, Sellak H. Invited review: cGMP-dependent proteinkinase signaling mechanisms in smooth muscle: from the regulation oftone to gene expression. J Appl Physiol 91: 1421-1430, 2001.
26. Mergia E, Russwurm M, Zoidl G, Koesling D. Major occurrence of thenew alpha2beta1 isoform of NO-sensitive guanylyl cyclase in brain. CellSignal 15: 189-195, 2003.
27. Mohan P, Brutsaert DL, Paulus WJ, Sys SU. Myocardial contractileresponse to nitric oxide and cGMP. Circulation 93: 1223-1229, 1996.
28. Mongillo M, McSorley T, Evellin S, Sood A, Lissandron V, Terrin A, Huston E, Hannawacker A, Lohse MJ, Pozzan T, Houslay MD, Zaccolo M. Fluorescence resonance energy transfer-based analysis ofcAMP dynamics in live neonatal rat cardiac myocytes reveals distinctfunctions of compartmentalized phosphodiesterases. Circ Res 95: 67-75,2004.
29. Pokreisz P, Vandenwijngaert S, Bito V, Van den Bergh A, Lenaerts I, Busch C, Marsboom G, Gheysens O, Vermeersch P, Biesmans L, Liu X, Gillijns H, Pellens M, Van Lommel A, Buys E, Schoonjans L, Vanhaecke J, Verbeken E, Sipido K, Herijgers P, Bloch KD, Janssens SP. Ventricular phosphodiesterase-5 expression is increased in patientswith advanced heart failure and contributes to adverse ventricular remodelingafter myocardial infarction in mice. Circulation 119: 408-416, 2009.
30. Preckel B, Kojda G, Schlack W, Ebel D, Kottenberg K, Noack E, Thamer V. Inotropic effects of glyceryl trinitrate and spontaneous NOdonors in the dog heart. Circulation 96: 2675-2682, 1997.
31. Prendergast BD, MacCarthy P, Wilson JF, Shah AM. Nitric oxideenhances the inotropic response to beta-adrenergic stimulation in theisolated guinea-pig heart. Basic Res Cardiol 93: 276-284, 1998.
32. Reffelmann T, Kloner RA. Therapeutic potential of phosphodiesterase 5inhibition for cardiovascular disease. Circulation 108: 239-244, 2003.
33. Sandirasegarane L, Diamond J. The nitric oxide donors, SNAP and DEA/NO, exert a negative inotropic effect in rat cardiomyocytes which is independentof cyclic GMP elevation. J Mol Cell Cardiol 31: 799-808, 1999.
34. Schmidt P, Schramm M, Schroder H, Stasch JP. Mechanisms of nitricoxide independent activation of soluble guanylyl cyclase. Eur J Pharmacol468: 167-174, 2003.
35. Senzaki H, Smith CJ, Juang GJ, Isoda T, Mayer SP, Ohler A, Paolocci N, Tomaselli GF, Hare JM, Kass DA. Cardiac phosphodiesterase 5(cGMP-specific) modulates beta-adrenergic signaling in vivo and is downregulatedin heart failure. FASEB J 15: 1718-1726, 2001.
36. Sinnaeve P, Chiche JD, Nong Z, Varenne O, Van Pelt N, Gillijns H, Collen D, Bloch KD, Janssens S. Soluble guanylate cyclase alpha(1) andbeta(1) gene transfer increases NO responsiveness and reduces neointimaformation after balloon injury in rats via antiproliferative and antimigratoryeffects. Circ Res 88: 103-109, 2001.
37. Solaro RJ, Moir AJ, Perry SV. Phosphorylation of troponin I and theinotropic effect of adrenaline in the perfused rabbit heart. Nature 262:615-617, 1976.
38. Stangherlin A, Gesellchen F, Zoccarato A, Terrin A, Fields LA, Berrera M, Surdo NC, Craig MA, Smith G, Hamilton G, Zaccolo M. cGMP signals modulate cAMP levels in a compartment-specific manner toregulate catecholamine-dependent signaling in cardiac myocytes. Circ Res108: 929-939, 2011.
39. Stasch JP, Becker EM, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, Gerzer R, Minuth T, Perzborn E, Pleiss U, Schroder H, Schroeder W, Stahl E, Steinke W, Straub A, Schramm M. NO-independent regulatorysite on soluble guanylate cyclase. Nature 410: 212-215, 2001.
40. Stasch JP, Schmidt P, Alonso-Alija C, Apeler H, Dembowsky K, Haerter M, Heil M, Minuth T, Perzborn E, Pleiss U, Schramm M, Schroeder W, Schroder H, Stahl E, Steinke W, Wunder F. NO- andhaem-independent activation of soluble guanylyl cyclase: molecular basisand cardiovascular implications of a new pharmacological principle. Br JPharmacol 136: 773-783, 2002.
41. Su J, Scholz PM, Weiss HR. Differential effects of cGMP produced bysoluble and particulate guanylyl cyclase on mouse ventricular myocytes. Exp Biol Med (Maywood) 230: 242-250, 2005.
42. Takimoto E, Belardi D, Tocchetti CG, Vahebi S, Cormaci G, Ketner EA, Moens AL, Champion HC, Kass DA. Compartmentalization ofcardiac beta-adrenergic inotropy modulation by phosphodiesterase type 5. Circulation 115: 2159-2167, 2007.
43. Takimoto E, Champion HC, Belardi D, Moslehi J, Mongillo M, Mergia E, Montrose DC, Isoda T, Aufiero K, Zaccolo M, Dostmann WR, Smith CJ, Kass DA. cGMP catabolism by phosphodiesterase 5Aregulates cardiac adrenergic stimulation by NOS3-dependent mechanism. Circ Res 96: 100-109, 2005.
44. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, Bedja D, Gabrielson KL, Wang Y, Kass DA. Chronic inhibition ofcyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 11: 214-222, 2005.
45. Vandecasteele G, Verde I, Rucker-Martin C, Donzeau-Gouge P, Fischmeister R. Cyclic GMP regulation of the L-type Ca(2+) channelcurrent in human atrial myocytes. J Physiol 533: 329-340, 2001.
46. Wang H, Kohr MJ, Traynham CJ, Ziolo MT. Phosphodiesterase 5restricts NOS3/soluble guanylate cyclase signaling to L-type Ca(2+)current in cardiac myocytes. J Mol Cell Cardiol 47: 304-314. 2009.
47. Wegener JW, Godecke A, Schrader J, Nawrath H. Effects of nitricoxide donors on cardiac contractility in wild-type and myoglobin-deficientmice. Br J Pharmacol 136: 415-420, 2002.
48. Wegener JW, Nawrath H, Wolfsgruber W, Kuhbandner S, Werner C, Hofmann F, Feil R. cGMP-dependent protein kinase I mediates thenegative inotropic effect of cGMP in the murine myocardium. Circ Res90: 18-20, 2002.
49. Ziolo MT, Harshbarger CH, Roycroft KE, Smith JM, Romano FD, Sondgeroth KL, Wahler GM. Myocytes isolated from rejecting transplantedrat hearts exhibit a nitric oxide-mediated reduction in the calciumcurrent. J Mol Cell Cardiol 33: 1691-1699, 2001.
50. Ziolo MT, Katoh H, Bers DM. Expression of inducible nitric oxidesynthase depresses beta-adrenergic-stimulated calcium release from thesarcoplasmic reticulum in intact ventricular myocytes. Circulation 104:2961-2966, 2001.
51. Ziolo MT, Lewandowski SJ, Smith JM, Romano FD, Wahler GM. Inhibition of cyclic GMP hydrolysis with zaprinast reduces basal andcyclic AMP-elevated L-type calcium current in guinea-pig ventricularmyocytes. Br J Pharmacol 138: 986-994, 2003.